Inimmune Corporation and Intrommune Therapeutics announce collaboration to advance a rapid, long-acting oral mucosal allergy immunotherapy for the treatment of peanut allergy
This revolutionary new immunotherapy will combine Intrommune’s disease-modifying treatment through its peanut oral mucosal immunotherapy (OMIT), with the rapid desensitization to allergens provided by Inimmune’s clinical stage proprietary immunotherapy.
